Abstract: The present disclosure is related to a method of identifying a subject with increased sensitivity to warfarin. The method includes identifying a CYP2C9*8 polymorphism in the subject, wherein the presence of said polymorphism is indicative of a patient with increased sensitivity to warfarin relative to a subject having the corresponding wild-type allele.

Abstract: To detect LSD in biological samples, antibodies are raised to LSD conjugated to a protein carrier, preferably through the indole ring. Selected antibodies are matched with an immunoassay reagent in which the LSD is conjugated in the same position to a labeling or separation means. The set of reagents can be used in immunoassays with remarkably little cross-reactivity with potential interfering substances such a chlorpromazine and ergotamine, and a low false-positive rate in a panel of clinical test samples. Also provided is a set of reagents for measuring glucuronide metabolites of LSD by immunoassay, which permits exposure to LSD to be determined over a longer diagnostic window.